Actively Recruiting
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Led by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Updated on 2026-03-13
60
Participants Needed
3
Research Sites
874 weeks
Total Duration
On this page
Sponsors
S
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk solid tumors.
CONDITIONS
Official Title
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Presence of a suitable related HLA-haploidentical bone marrow donor matching at least 5 of 10 alleles
- Age between 1 year and 50 years
- Confirmed high-risk solid tumor with expected survival less than 10%, including neuroblastoma, rhabdomyosarcoma, metastatic Ewing sarcoma, osteosarcoma with advanced metastases, desmoplastic small round cell tumor, or other similar tumors
- Prior standard therapy received; patients relapsing after autologous bone marrow transplant eligible if over 6 months have passed since last transplant
- Recovery from acute toxicities of prior treatments
- Stable disease if measurable, confirmed by scans at least 6 weeks apart
- Adequate organ function: heart ejection fraction ≥35% or shortening fraction >25%, bilirubin ≤3.0 mg/dL, liver enzymes less than 5 times upper limit, renal function normal or creatinine clearance >40 mL/min/1.73m2, lung function with FEV1, FVC, and DLCO >50% predicted or oxygen saturation >92% on room air
- Good performance status (Karnofsky or Lansky score 60-100)
- Ability of patient or guardian and donor to sign consent forms
- Willingness to participate in all treatment stages
You will not qualify if you...
- HIV positive status
- Donor-recipient ABO incompatibility if a compatible donor is available
- Positive leukocytotoxic crossmatch
- Women who are pregnant or not using adequate contraception
- Uncontrolled infections including viral, bacterial, or fungal
- Donor under 0.5 years old
- Presence of recipient anti-donor HLA antibodies at levels not approved by the study team
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States, 21231
Actively Recruiting
2
Albert Einstein College of Medicine, Children's Hospital at Montefiore
The Bronx, New York, United States, 10467
Actively Recruiting
3
New York Medical Center/ Maria Fareri Children's Hospital
Valhalla, New York, United States, 10595
Actively Recruiting
Research Team
H
Heather Symons, MD, MHS
CONTACT
J
Jasmine Brooks, BA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here